The field of cancer research has increasingly focused on the inflammatory response in colorectal and ovarian cancers due to its significant role in tumor progression. Colorectal cancer (CRC), the third most prevalent malignancy globally, is closely linked to chronic inflammatory bowel diseases like Crohn's disease and ulcerative colitis, which elevate CRC risk. The tumor microenvironment (TME) in CRC is populated by diverse immune cells, such as neutrophils, macrophages, and lymphocytes, each contributing variably to tumor dynamics. Similarly, ovarian cancer (OC), the most lethal gynecological cancer, is often diagnosed at advanced stages, with inflammation playing a crucial role in its progression. Despite the ovaries' lack of direct exposure to gut bacteria, conditions like chronic pelvic inflammatory diseases and endometriosis are associated with increased OC risk. Recent studies have highlighted the need to identify specific inflammatory pathways and immune cell subsets that either promote or inhibit tumor growth, which is vital for developing targeted therapies. However, the multifaceted and context-dependent nature of the inflammatory response in these cancers presents a significant challenge, necessitating a deeper understanding of the immune mechanisms involved.
This Research Topic aims to provide a forum for updating and discussing new discoveries in the field of inflammatory response in the progression of colon and ovarian cancers, with a particular focus on the cellular and molecular mechanisms driving immuno-pathogenesis. The primary objective is to explore the complex link between inflammation and tumor progression in these malignancies, ultimately aiming to develop customized treatments based on fundamental principles. By leveraging recent advances in single-cell sequencing, spatial transcriptomics, and artificial intelligence, the research seeks to identify targetable pathways and markers, develop personalized therapeutic strategies, and predict and monitor treatment responses.
To gather further insights into the inflammatory response in colorectal and ovarian cancers, we welcome articles addressing, but not limited to, the following themes:
• Unveiling the heterogeneity of inflammation: differentiating pro- and anti-tumor inflammatory markers in colorectal and ovarian cancers.
• Understanding molecular and cellular orchestration: identifying cytokines, chemokines, and growth factors that promote tumor growth and immune suppression.
• Identifying and validating druggable targets in pro-tumor inflammation pathways for novel drug development.
• Integrating genetic and molecular data with inflammatory response for individualized risk assessment and treatment selection.
• Analysis of large datasets using machine learning (ML) and artificial intelligence (AI) to find new therapeutic targets and patient subgroups.
• Future directions and emerging technology for understanding the inflammatory response in colorectal and ovarian malignancies.
Topic Editor Dr. Khurum Khan has an affiliation with The London Clinic, London, United Kingdom, and practicing privileges at HCA Healthcare UK, London, United Kingdom.
The field of cancer research has increasingly focused on the inflammatory response in colorectal and ovarian cancers due to its significant role in tumor progression. Colorectal cancer (CRC), the third most prevalent malignancy globally, is closely linked to chronic inflammatory bowel diseases like Crohn's disease and ulcerative colitis, which elevate CRC risk. The tumor microenvironment (TME) in CRC is populated by diverse immune cells, such as neutrophils, macrophages, and lymphocytes, each contributing variably to tumor dynamics. Similarly, ovarian cancer (OC), the most lethal gynecological cancer, is often diagnosed at advanced stages, with inflammation playing a crucial role in its progression. Despite the ovaries' lack of direct exposure to gut bacteria, conditions like chronic pelvic inflammatory diseases and endometriosis are associated with increased OC risk. Recent studies have highlighted the need to identify specific inflammatory pathways and immune cell subsets that either promote or inhibit tumor growth, which is vital for developing targeted therapies. However, the multifaceted and context-dependent nature of the inflammatory response in these cancers presents a significant challenge, necessitating a deeper understanding of the immune mechanisms involved.
This Research Topic aims to provide a forum for updating and discussing new discoveries in the field of inflammatory response in the progression of colon and ovarian cancers, with a particular focus on the cellular and molecular mechanisms driving immuno-pathogenesis. The primary objective is to explore the complex link between inflammation and tumor progression in these malignancies, ultimately aiming to develop customized treatments based on fundamental principles. By leveraging recent advances in single-cell sequencing, spatial transcriptomics, and artificial intelligence, the research seeks to identify targetable pathways and markers, develop personalized therapeutic strategies, and predict and monitor treatment responses.
To gather further insights into the inflammatory response in colorectal and ovarian cancers, we welcome articles addressing, but not limited to, the following themes:
• Unveiling the heterogeneity of inflammation: differentiating pro- and anti-tumor inflammatory markers in colorectal and ovarian cancers.
• Understanding molecular and cellular orchestration: identifying cytokines, chemokines, and growth factors that promote tumor growth and immune suppression.
• Identifying and validating druggable targets in pro-tumor inflammation pathways for novel drug development.
• Integrating genetic and molecular data with inflammatory response for individualized risk assessment and treatment selection.
• Analysis of large datasets using machine learning (ML) and artificial intelligence (AI) to find new therapeutic targets and patient subgroups.
• Future directions and emerging technology for understanding the inflammatory response in colorectal and ovarian malignancies.
Topic Editor Dr. Khurum Khan has an affiliation with The London Clinic, London, United Kingdom, and practicing privileges at HCA Healthcare UK, London, United Kingdom.